

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025**SECTION 1. IDENTIFICATION**

Product name : XOFLUZA Granules for Oral Susp. 2 mg/ml

Product code : RO719-1686/F08-00

Manufacturer or supplier's details

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way
South San Francisco, CA 94080
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

Recommended use of the chemical and restrictions on use

Recommended use : Formulated pharmaceutical active substance

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)**

Combustible dust

Carcinogenicity : Category 1A

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : May form combustible dust concentrations in air.
H350 May cause cancer.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025**Storage:**

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Baloxavir Marboxil	1985606-14-1	2
D-Mannitol	69-65-8	56
D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-	585-88-6	35
Sodium chloride (NaCl)	7647-14-5	3
Silica	7631-86-9	2
2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8	1
Sucralose	56038-13-2	0.5
Hydroxypropyl methylcellulose acetate succinate	71138-97-1	0.3
Strawberry Flavour	Not Assigned	0.1
Talc (Mg ₃ H ₂ (SiO ₃) ₄)	14807-96-6	0.1

SECTION 4. FIRST AID MEASURES

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact : Wash off with soap and water.

In case of eye contact : Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.

Most important symptoms and effects, both acute and : May cause cancer.

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

delayed

Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing

Notes to physician : Treat symptomatically.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Carbon oxides
Gaseous hydrogen chloride (HCl).
Sodium oxides
Hydrogen fluoride
Sulfur oxides
Nitrogen oxides (NO_x)

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Avoid dust formation.
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Pick up and arrange disposal without creating dust.
Sweep up and shovel.
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

XOFLUZA Granules for Oral Susp. 2 mg/ml

 Version
 1.1

 Revision Date:
 08/05/2025

 Date of last issue: 06/16/2025
 Date of first issue: 06/16/2025

- Advice on protection against fire and explosion : Provide appropriate exhaust ventilation at places where dust is formed.
- Advice on safe handling : For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.
- Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.
- Materials to avoid : No materials to be especially mentioned.
- Storage temperature : Protect from heat and light
Protect from moisture.
- Further information on storage stability : No decomposition if stored and applied as directed.
- Packaging material : Suitable material: Stainless steel, Polyethylene bag in metal drum, glass

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Silica	7631-86-9	PEL (respirable)	0.05 mg/m3	OSHA CARC
		TWA (Respirable dust)	0.05 mg/m3 (Silica)	NIOSH REL
Baloxavir Marboxil	1985606-14-1	IOEL	0.0025 mg/m3	Roche Industrial Hygiene Committee (RIHC)
Substance name		Environmental Compartment		Value
Baloxavir Marboxil		Surface waters		9.2 µg/l
		Remarks:Based on chronic data, Information refers to the main ingredient.		

Personal protective equipment

- Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

In case of contact through splashing:

Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:

Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : General industrial hygiene practice.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : granules

Color : white, light yellow

Odor : Not applicable

Odor Threshold : Not applicable

pH : Not applicable

Melting point/ range : No data available

Boiling point/boiling range : No data available

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Vapor pressure	: No data available
Relative vapor density	: Not applicable
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Solubility in other solvents	: No data available
Partition coefficient: n-octanol/water	: No data available
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, dynamic	: Not applicable
Viscosity, kinematic	: Not applicable
Explosive properties	: Not explosive
Oxidizing properties	: No data available
Particle characteristics	
Particle Size Distribution	: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: No dangerous reaction known under conditions of normal use.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Stable under recommended storage conditions. No hazards to be specially mentioned. Dust may form explosive mixture in air.
Conditions to avoid	: No data available No data available
Incompatible materials	: No data available Not applicable
Hazardous decomposition products	: No data available

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Acute toxicity**

Not classified due to lack of data.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:**D-Mannitol:**

Acute oral toxicity : LD50 Oral (Rat): 13,500 mg/kg
LD50 Oral (Mouse): 22,000 mg/kg

Acute inhalation toxicity : Acute toxicity estimate: > 30 mg/l
Test atmosphere: dust/mist
Method: Expert judgment

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Expert judgment

Sodium chloride (NaCl):

Acute oral toxicity : LD50 Oral (Rat): 3,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 Dermal (Rabbit): > 10,000 mg/kg

Silica:

Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg
GLP: yes

Acute inhalation toxicity : LC50 (Rat, male and female): > 5.01 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 436
GLP: yes

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 Dermal (Rabbit): > 5,000 mg/kg
Method: No information available.
GLP: No information available.

Baloxavir Marboxil:

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg

Skin corrosion/irritation

Not classified due to lack of data.

Components:**Sodium chloride (NaCl):**

Species : Rabbit
Result : No skin irritation

Silica:

Species : Rabbit
Exposure time : 4 h
Method : OECD Test Guideline 404
Result : No skin irritation
GLP : No information available.

Serious eye damage/eye irritation

Not classified due to lack of data.

Components:**Sodium chloride (NaCl):**

Species : Rabbit
Result : No eye irritation

Silica:

Species : Rabbit
Result : No eye irritation
Exposure time : 24 h
GLP : no

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

Respiratory sensitization

Not classified due to lack of data.

Components:**Silica:**

Test Type : Maximization Test
Species : Guinea pig
Assessment : Does not cause skin sensitization.
Method : OECD Test Guideline 406
Result : Did not cause sensitization on laboratory animals.
GLP : yes

Germ cell mutagenicity

Not classified due to lack of data.

Components:**Sodium chloride (NaCl):**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)
Metabolic activation: with and without metabolic activation
Method: Mutagenicity (micronucleus test)
Result: negative

Genotoxicity in vivo : Test Type: Chromosome aberration test in vitro
Species: Rat (female)
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 475
Result: positive

Silica:

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)
Test system: Salmonella typhimurium
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 471
Result: negative
GLP: yes

Test Type: Microbial mutagenesis assay (Ames test)
Test system: Escherichia coli
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 471
Result: negative
GLP: yes

Test Type: In vitro mammalian cell gene mutation test
Test system: mouse lymphoma cells

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 490
Result: negative
GLP: yes

Genotoxicity in vivo : Species: Rat (male)
Cell type: Bone marrow
Application Route: Oral
Method: OECD Test Guideline 475
Result: negative
GLP: no

Baloxavir Marboxil:

Genotoxicity in vitro : Method: Mutagenicity (Salmonella typhimurium - reverse mutation assay)
Result: negative

Method: OECD Test Guideline 473
Result: negative

Genotoxicity in vivo : Method: OECD Test Guideline 474
Result: negative

Carcinogenicity

May cause cancer.

Components:**D-Mannitol:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Silica:

Species : Rat, male and female
Application Route : Oral
Exposure time : 2 Years
Method : No information available.
Result : negative

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

GLP : No information available.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.**OSHA** OSHA specifically regulated carcinogen
Silica 7631-86-9
(crystalline silica)**NTP** Known to be human carcinogen
Silica 7631-86-9
(Silica, Crystalline (Respirable Size))**Reproductive toxicity**

Not classified due to lack of data.

Components:**Silica:**Effects on fertility : Species: Rat, male and female
Application Route: Oral
Dose: 100, 300, 1000 mg/kg bw/day
General Toxicity Parent: NOAEL: \geq 1,000 mg/kg body weight
General Toxicity F1: NOAEL: \geq 1,000 mg/kg body weight
Method: OECD Test Guideline 416
GLP: yesEffects on fetal development : Species: Mouse, female
Application Route: Oral
Dose: 13.4, 62.3, 289, 1340 mg/kg bw/day
Duration of Single Treatment: 6 - 15 d
General Toxicity Maternal: LOAEL: \geq 1,340 mg/kg bw/day
Embryo-fetal toxicity.: NOAEL: \geq 1,340 μ g/kg body weight
Method: No information available.
GLP: No information available.**Baloxavir Marboxil:**Effects on fetal development : Species: Rat
Application Route: Oral
Dose: 1000 milligram per kilogram
Duration of Single Treatment: 12 d
Result: No effects on fetal development.Species: Rabbit
Application Route: Oral
Dose: 100 milligram per kilogram
Duration of Single Treatment: 12 d
Result: No effects on fetal development.

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025**STOT-single exposure**

Not classified due to lack of data.

Components:**D-Mannitol:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified due to lack of data.

Components:**D-Mannitol:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Repeated dose toxicity**Components:****Silica:**

Species : Rat, male and female
NOEL : 4000 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Method : OECD Test Guideline 408
GLP : yes

Baloxavir Marboxil:

Species : Rat
NOAEL : 2000 mg/kg bw/day
Application Route : Oral
Exposure time : 2 Weeks
Remarks : Subacute toxicity

Aspiration toxicity

Not classified due to lack of data.

Components:**D-Mannitol:**

No data available

Further information**Product:**

Remarks : No data available

XOFLUZA Granules for Oral Susp. 2 mg/ml

 Version
 1.1

 Revision Date:
 08/05/2025

 Date of last issue: 06/16/2025
 Date of first issue: 06/16/2025

Components:
D-Mannitol:

Remarks : Health injuries are not known or expected under normal use.

SECTION 12. ECOLOGICAL INFORMATION
Ecotoxicity
Components:
D-Mannitol:

 Toxicity to fish : LC50 (Fish): > 100 mg/l
 Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : > 1 mg/l

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Sodium chloride (NaCl):

 Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 7,650 mg/l
 Exposure time: 96 h

 LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l
 Exposure time: 96 h

 Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 874 mg/l
 Exposure time: 48 h
 Test Type: static test

 LC50 (Daphnia magna (Water flea)): 4,136 mg/l
 Exposure time: 48 h
 Test Type: static test
 Method: OECD Test Guideline 202

 Toxicity to algae/aquatic plants : EC50: 2,430 mg/l
 Exposure time: 120 h
 Test Type: static test
 Method: OECD Test Guideline 201

 Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 252 mg/l
 Exposure time: 33 d
 Test Type: flow-through test
 Method: OECD Test Guideline 210
 GLP: no

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia): 314 mg/l
Exposure time: 21 d
Test Type: semi-static test
Method: OECD Test Guideline 211

Ecotoxicology Assessment

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Silica:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 5,000 mg/l
End point: mortality
Exposure time: 96 h
Test Type: static test
Analytical monitoring: no
Method: OECD Test Guideline 203
GLP: no

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 10,000 mg/l
End point: Immobilization
Exposure time: 24 h
Test Type: static test
Analytical monitoring: no
Method: OECD Test Guideline 202
GLP: yes

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): > 173.1 mg/l
End point: Growth rate
Exposure time: 72 h
Test Type: static test
Analytical monitoring: yes
Method: OECD Test Guideline 201
GLP: yes

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : Lowest Observed Effect Concentration (Daphnia magna (Water flea)): 149.2 mg/l
End point: mortality
Exposure time: 21 d
Test Type: semi-static test
Analytical monitoring: yes
Method: OECD Test Guideline 211
GLP: yes

Toxicity to microorganisms : NOEC (activated sludge): 1,000 mg/l
End point: Respiration inhibition
Exposure time: 3 h

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025Test Type: static test
Analytical monitoring: no
Method: OECD Test Guideline 209
GLP: yes**Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Baloxavir Marboxil:Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10.6 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes
Remarks: average measured concentrationNOEC (Danio rerio (zebra fish)): 10.6 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes
Remarks: average measured concentrationToxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 17.4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
GLP: yes
Remarks: measured initial concentrationNOEC (Daphnia magna (Water flea)): 17.4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: measured initial concentrationToxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): 9.28 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: average measured concentrationNOErC (Desmodesmus subspicatus (green algae)): 1.75 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: average measured concentrationEyC50 (Desmodesmus subspicatus (green algae)): 4.76 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
GLP: yes
Remarks: average measured concentration

Toxicity to microorganisms : (activated sludge): Exposure time: 14 d

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Method: OECD Test Guideline 301F
GLP: yes
Remarks: no adverse influence on substrate biodegradation

Persistence and degradability**Components:****D-Mannitol:**

Biodegradability : Biodegradation: 68 %
Exposure time: 28 d

Sodium chloride (NaCl):

Biodegradability : Remarks: The methods for determining biodegradability are not applicable to inorganic substances.

Silica:

Biodegradability : Remarks: Not applicable

Baloxavir Marboxil:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: < 10 %
Exposure time: 28 d
Method: OECD Test Guideline 301F
GLP: yes

Physico-chemical : Method: OECD Test Guideline 301F
removability : Remarks: Not abiotically degradable

Bioaccumulative potential**Components:****D-Mannitol:**

Partition coefficient: n- : log Pow: -3.10
octanol/water

D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-:

Partition coefficient: n- : Remarks: No data available
octanol/water

Sodium chloride (NaCl):

Partition coefficient: n- : Remarks: Not applicable
octanol/water

Silica:

Partition coefficient: n- : Remarks: Not applicable
octanol/water

Baloxavir Marboxil:

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

Partition coefficient: n-octanol/water : log Pow: 2.24
Method: calculated, consensus of various QSARs

log Pow: 2.46 (77 °F / 25 °C)
pH: 5
Method: OECD Test Guideline 117
GLP: yes

log Pow: 2.45 (77 °F / 25 °C)
pH: 7
Method: OECD Test Guideline 117
GLP: yes

log Pow: 2.46 (77 °F / 25 °C)
pH: 9
Method: OECD Test Guideline 117
GLP: yes

Mobility in soil

No data available

Other adverse effects**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82
Protection of Stratospheric Ozone - CAA Section 602 Class I
Substances
Remarks: This product neither contains, nor was
manufactured with a Class I or Class II ODS as defined by the
U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A +
B).

Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with
local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste
handling site for recycling or disposal.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025**IMDG-Code**

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation**49 CFR**

Not regulated as a dangerous good

Special precautions for userRemarks : Not dangerous goods in the meaning of ADR/RID, ADN,
IMDG-Code, ICAO/IATA-DGR**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

SARA 311/312 Hazards : Combustible dust
Carcinogenicity**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations**Massachusetts Right To Know**

Silica 7631-86-9

Pennsylvania Right To KnowD-Mannitol 69-65-8
D-Glucitol, 4-O-.alpha.-D-glucopyranosyl- 585-88-6

XOFLUZA Granules for Oral Susp. 2 mg/ml

 Version
 1.1

 Revision Date:
 08/05/2025

 Date of last issue: 06/16/2025
 Date of first issue: 06/16/2025

Sodium chloride (NaCl)	7647-14-5
Silica	7631-86-9

Maine Chemicals of High Concern

Silica	7631-86-9
--------	-----------

Vermont Chemicals of High Concern
Washington Chemicals of High Concern
California Prop. 65

WARNING: This product can expose you to chemicals including Silica, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California List of Hazardous Substances

Silica	7631-86-9
2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8

California Regulated Carcinogens

Silica	7631-86-9
--------	-----------

The ingredients of this product are reported in the following inventories:

AIIC	: Not in compliance with the inventory
DSL	: This product contains the following components that are not on the Canadian DSL nor NDSL.
	Baloxavir Marboxil
	Sucralose
	Hydroxypropyl methylcellulose acetate succinate
	NOTUPDATED_non hazardous compounds
	Butyric acid ethyl ester
NZIoC	: On the inventory, or in compliance with the inventory
ENCS	: Not in compliance with the inventory
ISHL	: Not in compliance with the inventory
KECI	: Not in compliance with the inventory
PICCS	: Not in compliance with the inventory
IECSC	: Not in compliance with the inventory
TCSI	: Not in compliance with the inventory
TSCA	: Product contains substance(s) not listed on TSCA inventory.
TECI	: Not in compliance with the inventory

XOFLUZA Granules for Oral Susp. 2 mg/ml

 Version
 1.1


 Revision Date:
 08/05/2025

 Date of last issue: 06/16/2025
 Date of first issue: 06/16/2025

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION
Further information
NFPA 704:

HMIS® IV:

HEALTH	*	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

NIOSH REL : USA. NIOSH Recommended Exposure Limits
 OSHA CARC : OSHA Specifically Regulated Chemicals/Carcinogens
 NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
 OSHA CARC / PEL : Permissible exposure limit (PEL)

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50

XOFLUZA Granules for Oral Susp. 2 mg/mlVersion
1.1Revision Date:
08/05/2025Date of last issue: 06/16/2025
Date of first issue: 06/16/2025

- Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 08/05/2025

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2404